A Phase 3 interventional study of DLBS3233 and Placebo of DLBS3233 in Prediabetic, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2012-08-07.
Sponsored by Dexa Medica Group · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia — 9 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Indonesia.
Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, this one is the 27th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2011, is one of 9 in phase 3, and was the 18th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →9 of the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia are open now. Recruiting first, the newest first:
Universitas Sriwijaya · Sites in Indonesia
Ages 30–65
Novo Nordisk A/S · Sites in Indonesia, Malaysia, Philippines and 1 more country
Ages 40–70
Indonesia University · Sites in Indonesia
Ages 35–59
Boryung Pharmaceutical Co., Ltd · Sites in Indonesia, Korea, Republic of
Ages 19+
Indonesia University · Sites in Indonesia
Ages 8–40 · Healthy volunteers
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 10 · Phase 4 8
First in 2003; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 85 across the 52 interventional studies, 1,750 across the 14 observational. Of the 47 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 66 have an industry lead sponsor. The 10 most frequent:
Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.
Dexa Medica Group has 5 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetes Mellitus, Type 2 with a site in Indonesia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT07064486Phase 3BrightGene Bio-Medical Technology Co., Ltd.A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | 2027-04-30 |
| NCT07928661Universitas SriwijayaEffect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes | 2026-12 |
| NCT07532863Novo Nordisk A/SA Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants | 2027-03-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 2-arm, prospective, double blind, randomized, and controlled clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of DLBS3233.
It is hypothesized that DLBS3233 will delay the progress of beta-cell dysfunction as measured by the improvement of prandial (particularly the first phase) insulin secretion as well as insulin resistance in prediabetic subjects which may prevent the conversion of prediabetes into type 2 diabetes mellitus.
There will be two groups of treatment in this study who will receive DLBS3233 or placebo of DLBS3233 for 12 weeks of therapy.
Subjects will be provided with an education on lifestyle modification given by the assigned nutritionist. All subjects will be advised to follow such a lifestyle modification throughout the study period.
All subjects will be under direct supervision of a medical doctor during the study period.
All clinical and laboratory examinations to evaluate the investigational drug's efficacy, will be performed at baseline, Week 8th and Week 12th (end) of study treatment. Blood glucose level (both FPG and 2h-PG) will be performed at baseline and at interval of 4 weeks over the 12 weeks of study treatment. Safety examinations will be performed at baseline and at the end of study. Occurrence of adverse event will be observed during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DLBS3233
Drug: Placebo of DLBS3233
For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
Also known as: Inlacin
For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
Change in 15-minute post prandial insulin level
Change in 15-minute post prandial insulin level from baseline to 12 weeks of treatment
Time frame: 12 weeks of treatment
Change in 15-minute post prandial insulin level
Change in 15-minute post prandial insulin level from baseline to 8 weeks of treatment
Time frame: 8 weeks of treatment
Change in 2-hour post prandial insulin level
Change in 2-hour post prandial insulin level from baseline to 8 weeks and to 12 weeks of treatment
Time frame: 8 weeks and 12 weeks of treatment
Change in 15-minute post prandial plasma glucose
Change in 15-minute post prandial plasma glucose from baseline to 8 weeks and to 12 weeks of treatment
Time frame: 8 weeks and 12 weeks of treatment
Change in 2-hour post prandial plasma glucose
Change in 2-hour post prandial plasma glucose from baseline to each study visit (4 weeks, 8 weeks, and 12 weeks of treatment)
Time frame: 4 weeks, 8 weeks, and 12 weeks of treatment
Change in HOMA-IR
Change in HOMA-IR from baseline to 8 weeks and to 12 weeks of treatment
Time frame: 8 weeks and 12 weeks of treatment
Change in hs-CRP
Change in hs-CRP from baseline to 8 weeks and to 12 weeks of treatment
Time frame: 8 weeks and 12 weeks of treatment
Improvement in lipid profile
Improvement in lipid profile from baseline to 8 weeks and to 12 weeks of treatment, including: fasting plasma HDL-cholesterol, fasting plasma triglyceride, 15-minute post prandial plasma triglyceride, and 2-hour post prandial plasma triglyceride
Time frame: 8 weeks and 12 weeks of treatment
Change in adiponectin
Change in adiponectin from baseline to 8 weeks and to 12 weeks of treatment
Time frame: 8 weeks and 12 weeks of treatment
Change in waist-to-hip ratio
Change in waist-to-hip ratio from baseline to each of study visit (4 weeks, 8 weeks, and 12 weeks of treatment)
Time frame: 4 weeks, 8 weeks, and 12 weeks of treatment
ECG
ECG will be evaluated at baseline and at end of study (12 weeks of treatment)
Time frame: 12 weeks of treatment
Vital signs
Vital signs (systolic and diastolic blood pressure, heart rate, respiration rate) will be evaluated at baseline and at each study visit (4 weeks, 8 weeks, and 12 weeks of treatment)
Time frame: 4 weeks, 8 weeks, and 12 weeks of treatment
Body weight
Body weight will be evaluated at baseline and at each study visit (4 weeks, 8 weeks, and 12 weeks of treatment)
Time frame: 4 weeks, 8 weeks, and 12 weeks of treatment
Liver function
Liver function (levels of serum ALT, γ-GT, alkaline phosphatase) will be evaluated at baseline and at end of study (12 weeks of treatment)
Time frame: 12 weeks of treatment
Renal function
Renal function (serum creatinine level) will be evaluated at baseline and at end of study (12 weeks of treatment)
Time frame: 12 weeks of treatment
Adverse events
Adverse events as well as number of subjects experienced the events will be observed and evaluated during study period (12 weeks) and until all adverse events have been recovered or stabilized
Time frame: 1-12 weeks of treatment
The record gives a start of Nov 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DLBS3233